longevity
(31)
Wei-Wu He
Wei-Wu He is a scientist, inventor, entrepreneur and investor who serves as Executive Chairman and CEO of Human Longevity, Inc., the San Francisco Bay Area precision-health company that pairs whole-genome sequencing with advanced imaging and blood analytics to catch age-related disease early. Trained as a molecular biologist at Baylor College of Medicine with an MBA from Wharton, he was among the first scientists at Human Genome Sciences before building OriGene Technologies into a major research-tools business. Over three decades he has founded or funded dozens of biotech companies through his venture fund Emerging Technology Partners, and he now channels that experience into the science of extending healthy human lifespan.
Nikolina Lauc
Nikolina Lauc is co-founder and CEO of GlycanAge, a UK-based longevity diagnostics company built on two decades of glycobiology research from her father's laboratory in Zagreb. A serial entrepreneur since 18, she runs a business that translates a blood-based glycan test into a biological age readout, and she has become one of the more visible operators pushing preventive-health testing into the consumer market.
Rony Sellam
Rony Sellam is the CEO of InsideTracker, a Cambridge, Massachusetts based personalized-health company that uses blood biomarkers, DNA and lifestyle data to give consumers actionable recommendations for extending healthspan. A former Deloitte consultant from France by way of Geneva and a longtime healthcare IT executive, he has run InsideTracker for over a decade and helped push the company past 100,000 members and into partnerships with Oura and Fitness SF.
John Ramunas
John Ramunas, PhD, is the Co-Founder and CEO of Rejuvenation Technologies Inc., a Mountain View, CA biotechnology company pioneering mRNA-based telomere extension therapy to reverse cellular aging. A serial entrepreneur turned neuroscientist, Ramunas spent his PhD at Stanford's Baxter Laboratory for Stem Cell Biology inventing the first safe, nonimmunogenic TERT mRNA drug - a technology now protected by 50+ patents. His company, backed by Khosla Ventures and Y Combinator, is advancing a pipeline targeting fatal orphan diseases including idiopathic pulmonary fibrosis and liver cirrhosis, with the long-term vision of a single therapy taken every few years to prevent age-related disease.
Alina Su
Alina Su is the co-founder and CEO of Generation Lab, a San Francisco longevity startup building an at-home cheek-swab test that measures biological age across organs and systems. She got her first medical device patent at 15, founded the needle-free injection company NovaXS, left a Harvard Medical School PhD to commercialize aging science from UC Berkeley's Conboy Lab, and made Forbes 30 Under 30 in 2023. Generation Lab has raised about $11M and counts geneticist George Church and Aubrey de Grey among its advisors.
Ashley Zehnder
Ashley Zehnder is the co-founder and CEO of Fauna Bio, a Berkeley biotech mining the genomes of hibernating ground squirrels, bears and 452 other mammal species for drugs that could treat humans. A boarded avian veterinarian with a Stanford PhD in cancer biology, she had her career epiphany while giving chemotherapy to a parrot, when a faculty member asked in disbelief, 'Birds... get cancer?' That question convinced her the wall between animal and human medicine was an illusion. Fauna Bio's Convergence AI platform turns the survival tricks of extreme mammals into therapeutic targets, work that has drawn partnerships with Eli Lilly and Novo Nordisk and NASA-funded research into putting astronauts into a hibernation-like state.
Brad Berman
Brad Berman is the co-owner and CEO of BodyBio, a family-owned cellular-health and nutritional-supplement company in Millville, New Jersey. He arrived not from a lab but from the beverage aisle, with stops at PepsiCo and FIJI Water, and married into the founding Kane family. Since taking the top job in 2019 he has rebranded the 25-plus-year-old practitioner brand, pushed it into direct-to-consumer and mainstream retail, and steered roughly 41% revenue growth that landed BodyBio on the Inc. 5000.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.
Felix Wong
Felix Wong is the co-founder and CEO of Integrated Biosciences, a Redwood City biotech using synthetic biology, optogenetics and explainable AI to discover small-molecule drugs for age-related disease. A physicist and mathematician by training with a Harvard PhD in applied physics, he led the team that reported the first new structural class of antibiotics discovered with explainable deep learning - published in Nature in 2023 - and pioneered the AI-driven discovery of senolytics. He was named to the Forbes 30 Under 30 in Healthcare and has authored more than 30 papers in journals including Nature, Science and Cell.
Gabriel Tremblay
Gabriel Levesque-Tremblay is the CEO and co-founder of HexemBio, a New York and Berkeley biotech building what it calls the first scalable blood stem cell rejuvenation therapy. A synthetic biologist with a PhD from UBC and a postdoc at UC Berkeley, he is a two-time founder and Y Combinator alumnus who earlier co-founded the cultivated-meat startup Orbillion Bio. At HexemBio he turns aged hematopoietic stem cells young again by passing them through a recreated embryonic 'Synthetic Yolk Sac' before returning them by IV. The company closed a $10.4M seed round led by Draper Associates in April 2026 and is targeting first-in-human trials by 2027.
Rustam Sengupta
Rustam Sengupta is the founder and CEO of Tuktu Care, a Vancouver-born platform that matches older adults with vetted community helpers for companionship and everyday tasks so they can keep living at home. A serial entrepreneur who previously built solar microgrid companies across rural India, he turned a pandemic-era scramble to care for his aging parents in Singapore into a fast-growing agetech company backed by Techstars and Melinda French Gates' Pivotal Ventures. He holds an MBA from INSEAD, an MS in Electrical Engineering from UC Irvine, and a Chevening Fellowship from Oxford, and teaches social entrepreneurship at the University of Vermont.
Simon Cheng
Simon Cheng is the founder and CEO of Pique, a Los Angeles-based wellness company that turned whole-leaf tea into dissolvable crystals using a patented cold extraction process. A Hong Kong native who grew up drinking tea with his grandparents, Cheng abandoned those rituals in his teens, then spent his 20s cycling through surgeries and a decade of health crises. He rebuilt his health on a multi-year study trip across Asia learning from medicinal-plant and breathwork masters, and channeled that obsession into Pique, which launched in Whole Foods in 2016 and scaled to thousands of stores. Harvard and Stanford educated, and the youngest member of Harvard School of Public Health's Nutrition Roundtable, Cheng built Pique on three promises: efficacy, purity, and zero prep.
Tom Benson
Tom Benson is the founder and CEO of Mitrix Bio, a Pleasanton, California biotech building toward whole-body mitochondrial transplantation. A serial software, hardware, and science entrepreneur, he managed the Linac Coherent Light Source femtosecond X-ray laser at Stanford's SLAC before turning his attention to the cell's power plants. His pitch is audacious and specific: grow young mitochondria from a person's own stem cells in a bioreactor, then transfuse them back to restore cellular energy and push the human lifespan toward 130 years.
Scott Magargee
Scott Magargee is the CEO and co-founder of Springbok Analytics, a Charlottesville, Virginia company that turns ordinary MRI scans into FDA-cleared, AI-built 3D maps of every muscle in the human body. A former Princeton history major and Top 100 law firm litigator, he traded courtrooms for muscle health, joining the University of Virginia spinout in December 2019 and steering it through a $5M oversubscribed Series A in January 2025 backed by the NBA. Under his watch, Springbok has scanned elite athletes, pro basketball leagues, and clinical-trial patients, chasing a single idea: make muscle visible, measurable, and actionable.
Dugal Bain-Kim
Dugal Bain-Kim is the co-founder and CEO of Lifeforce, a clinically integrated health optimization platform he launched in February 2022 with Tony Robbins, Dr. Peter Diamandis and Joel Jackson. An Australian-born finance and healthcare operator who went from BlackRock and Cambridge to telehealth, he built Lifeforce after his own fragmented hunt for answers about his changing body at 38. The company tests 40+ biomarkers via at-home blood draws and pairs the data with clinicians, coaching and supplements, on a stated mission to extend healthy lifespan for five million people by 2030.
Eric Marcotulli
Eric Marcotulli is the co-founder and CEO of Elysium Health, a New York consumer health company he started in 2014 to turn academic aging research into products people can actually buy. A former wrestler who became Sequoia Capital's youngest partner before he turned 30, he left venture capital after a business-school case study on cellular aging convinced him that longevity was a solvable engineering problem, not a fairy tale. He built Elysium by recruiting Nobel laureates and a roster of world-class scientists as advisors, raising more than $70 million across several rounds, and selling directly to consumers.
Joe Betts-LaCroix
Joe Betts-LaCroix is the co-founder and CEO of Retro Biosciences, a San Francisco longevity biotech on a mission to add 10 healthy years to the human lifespan. A scientist-turned-serial-entrepreneur who once held a Guinness World Record for building the world's smallest Windows PC, he now leads a company backed by OpenAI's Sam Altman, valued at $1.8 billion in 2026, that has run an Alzheimer's clinical trial and co-developed a longevity-focused AI model with OpenAI. He came to biology by an unlikely route: a D-average high schooler who tinkered in shared houses, then earned straight A's, transferred to Harvard, and did research at MIT and Caltech before co-discovering principles of electron transfer in proteins.
Koji Tanabe
Koji Tanabe is the founder and CEO of I Peace, Inc., a Palo Alto and Kyoto biotech building an automated platform to mass-manufacture clinical-grade induced pluripotent stem cells (iPSCs). He earned his PhD in the Kyoto University lab of Nobel laureate Shinya Yamanaka and was a co-author of the landmark paper that first reported the creation of human iPS cells. After postdoctoral work at Stanford, he founded I Peace in 2015 with the goal of giving every person access to their own stem cells for therapy and longevity.
Saad Alam
Saad Alam is the co-founder and CEO of Hone Health, a telehealth platform built around preventative, biomarker-driven longevity care. After a year lost inside the conventional healthcare system, he set out to build the clinic he wished he'd found. Hone now counts hundreds of thousands of tested patients and closed a $33M Series A in early 2025, alongside the acquisition of in-home care company ivee. Before Hone, Alam co-founded the edtech company Citelighter and led market research for Eli Lilly's neuroscience franchise.
Andrew Lacy
Andrew Lacy is the Founder and CEO of Prenuvo, the company making proactive whole-body MRI scanning a mainstream healthcare tool. A Melbourne-born, Stanford-trained entrepreneur, he previously co-founded Tapulous - the mobile gaming company behind Tap Tap Revenge, acquired by Disney in 2010 - before pivoting to healthcare. At Prenuvo, he has raised $177M in total funding (including a $120M Series B in 2024), grown the company to 110,000+ members across 17 North American clinics, and secured FDA clearance for AI-powered body composition analysis, with plans to expand into Europe and Australia.
Celine Halioua
Celine Halioua is the founder and CEO of Loyal, a San Francisco biotech company developing the first FDA-approved drug for lifespan extension - starting with dogs. Born in Austin, Texas to a Moroccan mother and German father, she studied neuroscience at UT Austin and nanotechnology at Uppsala University before pursuing a DPhil at Oxford on the health economics of gene therapy. She left Oxford to join Laura Deming's Longevity Fund as Chief of Staff, then founded Loyal in 2019 at age 24. With $250M+ in total funding and the largest clinical trial ever conducted in animal health (1,300+ dogs across 70+ clinics), Loyal's lead drug LOY-002 has cleared FDA safety and efficacy hurdles - putting it on track to become the first longevity drug ever approved for any species.
Max Kholin
Maxim (Max) Kholin is the co-founder and COO of Gero, a physics-powered longevity biotech company applying statistical physics and AI to crack the biology of aging. With roots in contract law, international business, and computational drug design, he bridges the gap between cutting-edge science and real-world commercialization. Gero - which he co-founded with physicist Peter Fedichev in 2015 - has pioneered the field of 'Gerophysics,' trained its models on 100M+ longitudinal medical records, and secured partnerships with Pfizer and Chugai Pharmaceutical worth up to $250M in milestones. Based across Singapore and Palo Alto, Kholin's mission is nothing less than transforming humans into a non-aging species.
Peter Fedichev
Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.
Bryan Johnson
Bryan Johnson is an American tech entrepreneur who built and sold Braintree (the parent of Venmo) to PayPal for $800 million, then funneled the proceeds into venture firm OS Fund and neurotech startup Kernel. He is now best known for Blueprint, a personal protocol and commercial brand built around his 'Don't Die' philosophy, chronicled in the 2025 Netflix documentary 'Don't Die: The Man Who Wants to Live Forever.'
Elad Gil
Elad Gil is a Silicon Valley polymath - biologist-turned-Googler-turned-Twitter VP-turned-solo venture capitalist - who has backed 40+ unicorns including Airbnb, Stripe, Coinbase, Pinterest, and OpenAI. Managing $3+ billion as one of the largest solo GPs in venture history, he also co-founded Color Genomics, wrote the 'High Growth Handbook' (published by Stripe Press), and co-hosts the No Priors AI podcast with Sarah Guo. His blog (Elad Blog) reaches tens of thousands of readers on startups, AI, and longevity.
Francisco Leport
Francisco Leport is the co-founder and CEO of Gordian Biotechnology, a South San Francisco-based company pioneering high-throughput in vivo drug discovery for age-related diseases. Trained as a physicist at Stanford, Leport pivoted from particle physics and energy tech into biotech, driven by a lifelong fascination with longevity sparked by his mother's fruit fly research. Gordian's signature 'mosaic screening' platform uses gene therapy vectors and single-cell RNA sequencing to test hundreds of therapies simultaneously in single animal models, with an AI system called Pythia scoring results against human disease signatures - achieving 80% accuracy in predicting clinical outcomes. The company raised a $60M Series A in April 2024, backed by Founders Fund, Gigafund, and The Longevity Fund, and in early 2026 announced a research collaboration with Pfizer to accelerate obesity drug discovery.
Charles Hoskinson
Charles Hoskinson is the founder of Cardano and CEO of Input Output (IOHK), one of the five original co-founders of Ethereum, and a polarizing figure in cryptocurrency who left Ethereum over a for-profit vs. nonprofit dispute. He now runs a peer-reviewed blockchain platform, owns an 11,000-acre buffalo ranch in Wyoming, funds alien-hunting expeditions, donated $20 million to Carnegie Mellon for formal mathematics research, and is pioneering anti-aging medicine while building political influence through his Wyoming Integrity PAC.
Omri Amirav-Drory
Omri Amirav-Drory, Ph.D., is a General Partner at NFX leading NFX Bio, a pre-seed and seed venture fund focused on scientist-founders at the intersection of technology and biology. A former Fulbright Scholar and Stanford postdoc turned biotech entrepreneur, he co-founded Genome Compiler (acquired by Twist Bioscience), launched Tech.Bio, and now backs breakthrough life sciences companies while co-founding Renewal Bio - a longevity company building synthetic embryo-derived tissues to combat aging. His stated mission is ending involuntary death.
Peter Diamandis
Peter H. Diamandis is a Greek-American entrepreneur, physician, and futurist who has founded or co-founded 25+ companies and is best known as the creator of the XPRIZE Foundation - which has launched over $600 million in incentive competitions catalyzing $10+ billion in R&D. A data-driven optimist, he co-founded Singularity University with Ray Kurzweil, runs the Metatrends newsletter (157,000+ subscribers), and is a 4x New York Times bestselling author. His current mission centers on longevity - he launched the $101 million XPRIZE Healthspan in 2024 and published the Longevity Guidebook in January 2025.
Balaji Srinivasan
Balaji Srinivasan is a serial founder, investor, and author who holds four Stanford degrees and has co-founded companies sold for nearly half a billion dollars. Former General Partner at Andreessen Horowitz and first CTO of Coinbase, he is best known for writing The Network State — a WSJ #2 bestselling book advocating technology-enabled sovereign communities — and for building The Network School, a live experiment in startup-society living on a private island near Singapore.